Company / Working Capital
Vistagen Therapeutics, Inc. Working Capital History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$12.9M
FY2023
5-year range
$2.0M / $99.9M
FY2019-FY2023
Trend
-80.2%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $100M to $13M over the past 2 years.
Based on SEC 10-K filings.
$13M in FY2023 with a 5-year CAGR of +6.2%.
Declined from $100M to $13M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +6.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +6.2%, indicating consistent growth.
- In FY2023, working capital decreased 80.2% year-over-year.
- Peak working capital was recorded in FY2021.
- Lowest working capital in the period was in FY2012.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $12.9M | -80.2% |
| FY2022 | $65.2M | -34.7% |
| FY2021 | $99.9M | +944.8% |
| FY2018 | $9.6M | +375.8% |
| FY2017 | $2.0M | +215.4% |
| FY2014 | -$1.7M | +40.8% |
| FY2012 | -$2.9M | -0.0% |
| FY2011 | -$2.9M | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026